Integra Lifesciences Holdings Corp (NASDAQ:IART) reaffirmed FY22 revenue guidance at the midpoint of its August 2022 guidance of $1.551 billion – $1.563 billion with an estimate of $1.57 billion. It raised FY22 adj EPS outlook to $3.29 – $3.33 versus an estimate of $3.24.
Invest in Crocs—and Crocks—for Sure-Footed Gains
If you had told me decades ago when Crocs were born and Donald Trump was a game show host that the former, one of the most hideous pieces of footwear ever designed would become a mainstream fad and that the latter, one of the most reptilian of real estate moguls, would not only become president but would one day launch a public market venture with the world truth in the title, I would
